secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-05-01T23:59:59+00:00
Accession:  0001367644-24-000060
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent Q1 rev $300M, net income $9M; raises FY2024 adj EBITDA guidance to $125-175M
--------------------------------------------------------------------------------

- Q1 2024 total revenues $300.4M (up 83% YoY), net income $9.0M vs loss of $186.2M last year.
- Adjusted EBITDA $66.9M vs $(101.5)M; adjusted EPS $0.59 vs $(3.26).
- FY2024 guidance raised: total rev $1.0-1.1B, adj EBITDA $125-175M, adj net loss $(65)-(15)M.
- ASPR contract modification reduces minimum purchase from 9M to 3.5M doses annually for Option Years 5-9; max contract value revised to $1.4B.
- NARCAN sales up 18% to $118.5M; MCM segment gross margin improved to 60%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000060/0001367644-24-000060-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000060/ebs-20240429.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000060

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer